|Videos|July 15, 2021
An Overview of Aducanumab for the Treatment of Alzheimer Disease
Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.
Advertisement
In a recent interview with Pharmacy Times, Pamela Spicer, senior analyst with Datamonitor Healthcare at Informa Pharma Intelligence, reviewed the approval of aducanumab and what pharmacists should know about its use in patients with Alzheimer disease. Spicer said aducanumab is a once-monthly infusion with a 6-month titration schedule. It has several notable adverse effects, including amyloid-related imaging abnormalities which should be monitored closely.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
2
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
3
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
4
FDA Grants Orphan Drug Designation to Zavabresib for the Treatment of Myelofibrosis
5